NTD 400 Royal Pharmaceuticals

• Category: Injectable AAS Blend (Research Only)
• Brand: Royal Pharmaceuticals
• Total Concentration: 400 mg/ml
• Composition per ml: Nandrolone Decanoate 150 mg • Testosterone Enanthate 150 mg • Drostanolone Enanthate 100 mg
• Packaging: 10 1 ml ampoules
• Origin: United Kingdom
• Use Notice: Laboratory and analytical research only. Not for human or veterinary use.

What is NTD 400?

NTD 400 is a fixed-ratio research-grade combination of three long-acting anabolic–androgenic steroids (AAS):

• Nandrolone Decanoate – 150 mg/ml
• Testosterone Enanthate – 150 mg/ml
• Drostanolone Enanthate – 100 mg/ml

All three compounds are esterified androgens designed for intramuscular depot release. After injection, esterases gradually cleave each ester, resulting in prolonged exposure suitable for in-vitro, ex-vivo or controlled in-vivo research models.

Key Research Details

• Parameter
• Nandrolone Decanoate
• Testosterone Enanthate
• Drostanolone Enanthate

• Chemical Class
• 19-nor testosterone derivative
• Esterified endogenous androgen
• DHT-derived non-aromatising androgen

• Concentration in Blend
• 150 mg/ml
• 150 mg/ml
• 100 mg/ml

• Primary Receptor Target
• Androgen receptor
• Androgen receptor
• Androgen receptor

• Notable Features
• Strong anabolic, low aromatisation, progestogenic behavior
• Aromatises to estradiol; reference androgen
• Non-aromatising; mild anti-estrogenic behavior

Mechanism of Action

All components act as androgen receptor (AR) agonists. Once released from their esters, they bind intracellular ARs, migrate to the nucleus and regulate transcription of genes tied to:

• Protein synthesis
• Nitrogen retention
• Muscle fibre growth
• Erythropoiesis (RBC production)
• Bone and collagen metabolism

Nandrolone Decanoate

Enhanced anabolic: androgenic ratio; weak aromatisation; studied for anemia, wasting, and bone density models.

Testosterone Enanthate

Long-acting aromatising androgen; foundational model for androgen + estrogen interactions.

Drostanolone Enanthate

Non-aromatising DHT-derivative; investigated for androgenic effects without estrogenic conversion.

Research Overview

• Lean mass & strength: Increased muscle protein synthesis and fibre size in controlled models.
• Bone density: Effects on mineral density, osteoblast activity and collagen turnover.
• Erythropoiesis: Higher hemoglobin, hematocrit and reticulocyte counts.
• Endocrine suppression: Significant reductions in LH, FSH and endogenous testosterone.
• Mixed-androgen interaction: Useful in research comparing aromatising vs. non-aromatising androgens.
• Pharmacokinetic mapping: Modeling of staggered ester-release curves.

Side Effects & Safety Considerations

(Based on class-wide AAS data; not specific to this product.)

• Endocrine: HPG-axis suppression, infertility, testicular atrophy.
• Androgenic: Acne, seborrhoea, hair loss, virilisation in females.
• Cardiovascular: HDL, LDL, BP elevation, thrombosis risk.
• Hepatic/Metabolic: Enzyme elevations, altered glucose and lipid metabolism.
• Neuropsychiatric: Mood swings, aggression, sleep disturbances.
• Gynecomastia: Driven primarily by testosterone aromatisation; nandrolone may contribute via estrogenic/progestogenic pathways.
• Local reactions: Irritation, swelling or infection if aseptic technique is not followed.

Compliance & Legal Status

All components (nandrolone, testosterone esters, drostanolone) are controlled substances in many countries.

Classified under WADA S1 Anabolic Agents — prohibited at all times.

Supplied strictly as a research chemical by Royal Pharmaceuticals.

Not approved for therapeutic, bodybuilding, or performance use.

Technical Specifications

Intended Use

Laboratory / analytical research only

Storage

Cool, dry, protected from light

For laboratory research only. Not for human or veterinary administration.